British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...
GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline GSK could beat Pfizer to market, says chief commercial officer Several drugmakers are betting on mRNA seasonal flu vaccines ...
A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend ... as well as other ranitidine products – increased the risk of cancer.
Maraviroc is under clinical development by GSK and currently in Phase III for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
Products including untaxed cigarettes, vapes and banned medicine were found during a shop search. GSK Liquor Stop on Dudley ...
After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...
GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn drug Zantac causes cancer is scientifically sound. The British ...
Partnership is integral to GSK. Bringing people together is the best way to innovate and deliver products that transform the standard of care and improve lives. Over half of GSK’s clinical ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback